Walk into any shop selling CBD and you will see three terms everywhere: full spectrum, broad spectrum and isolate. They describe what else is in the bottle alongside the CBD — and the difference matters more than most packaging explains.
It matters for a practical reason too. Full-spectrum products contain THC, which has consequences for drug testing — and for whether they will continue to qualify as hemp under US federal law after November 2026.
The short version
- Full spectrum keeps the plant’s other cannabinoids and compounds, including trace THC.
- Broad spectrum retains some of the wider plant profile but is processed to remove or substantially reduce THC.
- Isolate is purified CBD on its own.
- CBD itself does not produce a high. Full-spectrum products retain THC, and the legal limit is a concentration, not a cap on the milligrams in a bottle.
- These are commercial rather than standardised scientific terms, and no label can guarantee either composition or a clean drug test. Check the laboratory report.
- Our view: for people who can take THC, full spectrum is a reasonable first choice — a reasoned preference, not a settled hierarchy.
Where the differences come from
The three categories often begin with the same basic material: an extract drawn from the flowering parts of the hemp plant, containing cannabinoids, terpenes, fatty acids and other plant components. What separates them is how much of that original mixture is retained during processing.
In the simplest pathway, retaining the widest range produces a full-spectrum extract. Further processing to remove THC produces broad spectrum. Continued purification down to CBD alone produces isolate.
Manufacturers can also build finished products by blending purified cannabinoids and other ingredients back together, which is another reason the label does not always tell the whole story.
Full spectrum
Full-spectrum extracts contain the widest range of the plant’s compounds — major and minor cannabinoids, terpenes and flavonoids — because the least has been removed. Hemp flower is broadly analogous, although spectrum terminology is used mainly for extracts.
It also contains THC. Under the definition currently in force, hemp may contain no more than 0.3% delta-9 THC by dry weight. To qualify as hemp, a full-spectrum product must remain within that limit.
Broad spectrum
Broad spectrum generally begins with a multi-compound hemp extract and undergoes further purification to remove or substantially reduce the THC. What remains should include CBD and at least some additional cannabinoids or plant compounds, although the precise composition varies considerably between products.
For anyone who wants to avoid THC — whether because of workplace testing, personal preference, or sensitivity to even small amounts — broad spectrum is the category designed for that.
Isolate
Isolate is purified CBD, typically arriving as a white crystalline powder. It is sold on its own and used as an ingredient in tinctures, capsules and edibles.
Its advantages are simplicity and dosing precision. A genuine isolate contains CBD without THC or minor cannabinoids, which makes it useful when carefully measured CBD-only dosing matters, or when a first-time user wants to eliminate other cannabinoids as variables. It has little distinctive taste or smell and is often less expensive than multi-compound extracts. An isolate label is still not a substitute for a batch-specific lab report.
The entourage effect, and where we stand
The argument for whole-plant preparations rests on the entourage effect: the possibility that cannabinoids, terpenes and other plant compounds behave differently together than they do in isolation.
The term originated in a 1998 study of endocannabinoids and related compounds. It was later extended to cannabis phytochemistry, most influentially in Ethan Russo’s 2011 review of possible interactions among plant cannabinoids and terpenes.[1] That review set out a persuasive pharmacological case for studying such interactions, but it did not establish that full-spectrum CBD products work better in people.
Our view is nevertheless that preserving the plant’s wider chemistry is a reasonable starting point when THC is acceptable. Full spectrum retains compounds that may contribute to a product’s effects; isolate removes them before we know conclusively whether they matter. That is an editorial preference based on biological plausibility and incomplete but suggestive evidence — not proof that full spectrum will work better for every person or condition.
One frequently cited source of support comes from treatment-resistant epilepsy. A 2018 meta-analysis of observational studies reported more general improvement, lower average CBD doses and fewer adverse effects among patients using CBD-rich extracts than among those using purified CBD.[2] But when the authors applied the standard threshold of at least a 50% reduction in seizures, they found no significant difference between the two groups. The studies were observational rather than randomised, and they did not compare the two preparations directly in equivalent patients.
The result is intriguing, particularly because benefits were reported at lower CBD doses. It does not settle the comparison. Differences between the underlying studies, products, patients and accompanying medications could also help explain the findings.
Purified CBD has the strongest formal clinical evidence in one important respect. The prescription treatment approved for several severe seizure disorders was tested in randomised controlled trials using a standardised form of CBD. That establishes the effectiveness of that particular medicine for those conditions. It does not establish that purified CBD is generally superior to a well-characterised CBD-rich extract.
The dominance of purified CBD in clinical research also reflects the requirements of drug development: exact composition, reproducible dosing and consistent manufacturing. Those are genuine advantages, especially in medicine. They should not be mistaken for evidence that removing every other plant compound produces the better treatment.
So our position is deliberately qualified. For people who can take THC, we think a well-made full-spectrum product is a reasonable first choice. Broad spectrum and isolate remain better options when avoiding THC, simplifying the formulation, or achieving tightly controlled CBD-only dosing matters more. “Full spectrum” on a label is not itself evidence of quality, effectiveness or value.
Can any of them get you high?
CBD itself does not produce the characteristic high associated with THC. Isolate contains no intentional THC, and a properly made broad-spectrum product should contain none, or only an amount below the laboratory’s detection limit.
Full-spectrum products are different, because they retain THC. Many contain too little to produce noticeable intoxication at the suggested serving — but that cannot be assumed from the words “full spectrum” or “hemp-derived” alone.
The important detail is how the federal limit works. It is a concentration — 0.3% by dry weight — not a limit on the total dose in a bottle, a gummy or a serving. A product can satisfy that threshold and still deliver a meaningful number of milligrams. Larger servings, more concentrated formulations and inaccurate labels all increase the amount actually consumed.
This is why a certificate of analysis should report THC in milligrams per serving and per container, not only as a percentage.
The risk is greater when a product contains more THC than its label claims — independent testing has repeatedly found this — or when it comes from a state-regulated cannabis market, where “CBD product” does not necessarily mean hemp-derived or non-intoxicating.
Drug testing is a separate question
Not getting high and not failing a drug test are two different things. Workplace screening looks for THC and its metabolites, not for intoxication. Trace amounts from regular full-spectrum use can accumulate sufficiently to trigger a positive result, and this has been documented.
If you are subject to testing, isolate or a thoroughly verified broad-spectrum product carries less risk than full spectrum — but no unregulated retail product can guarantee you will pass. Spectrum labels and “THC-free” claims are not always accurate.
What changes in November 2026
This is the part most guides have not caught up with. A law enacted on 12 November 2025 (Public Law 119-37) takes effect on 12 November 2026 and changes how hemp is defined in the United States.
It makes three changes that matter here:
- It replaces the delta-9-only plant threshold with a total tetrahydrocannabinols standard that includes THCA.
- It excludes final products containing cannabinoids the plant cannot naturally produce, or cannabinoids that were synthesised or manufactured outside the plant.
- It limits finished hemp-derived cannabinoid products to 0.4 mg per container of total THC and certain other cannabinoids placed in the law’s THC-like category. The container means the innermost retail packaging in direct contact with the product.
Full-spectrum products are the category most affected, since they are the ones designed to retain THC. Many products that qualify as hemp under today’s federal definition will not qualify under the new one. Bills to delay implementation have been introduced in both chambers — they would replace the one-year period with three, moving the date to November 2028 — but as of 31 July 2026 neither had advanced beyond committee.
One thing worth being clear about: qualifying as hemp does not automatically make a product lawful to sell. FDA rules for foods, supplements, cosmetics and drugs apply separately.
How to verify what you are actually buying
Because these are commercial terms rather than regulated categories, the label alone does not tell you what is in a product. The lab report does.
A current, batch-specific certificate of analysis from an independent laboratory should show:
- Full spectrum — CBD accompanied by other cannabinoids, with a measurable amount of THC consistent with the product’s description
- Broad spectrum — CBD accompanied by at least some other cannabinoids, with THC reported as not detected or below the laboratory’s stated reporting limit
- Isolate — CBD without measurable amounts of other cannabinoids
Terpenes may appear on a separate report. Their absence from a standard cannabinoid panel does not by itself establish that a product is isolate.
Two things worth looking for beyond the numbers. THC should be reported in milligrams per serving and per container, not only as a percentage — the percentage tells you about concentration, not about the dose you will actually take. And remember that “not detected” means below the laboratory’s reporting limit, not necessarily absolute zero.
Check too that the batch number matches the product in your hand, that the test date is recent, and that the report covers contaminants — pesticides, heavy metals, residual solvents and microbials — rather than potency alone. If a company will not supply a full report, that is itself information.
One thing that is none of the above
Hemp seed oil is pressed from seeds and contains little or no cannabinoid content. It is a culinary and cosmetic oil, not a CBD product. The two are confused constantly — sometimes accidentally, sometimes not — particularly in marketplace listings where a cheap “hemp oil” sits alongside genuine CBD products.
Choosing between them
In practice the decision comes down to a short sequence:
- Do you need to minimise THC exposure? If you are drug tested or strongly prefer to avoid THC, full spectrum carries the greatest risk. A verified broad-spectrum or isolate product is the more cautious choice, although neither can guarantee a negative test.
- Do you want the wider plant profile? If THC is not a concern and you would rather have the other cannabinoids and terpenes present, full spectrum contains the most of them — bearing in mind that whether this delivers a practical benefit is still an open question.
- Do you want simplicity? If you want carefully measured CBD-only dosing, no taste, or the fewest variables, isolate is the most predictable and often the least expensive.
Beyond that, responses vary considerably between individuals. General guidance about spectrums is a starting point, not a prescription, and the product that suits someone else may not suit you.
For the wider picture — how CBD works, what the evidence supports, safety and interactions — see our guide to CBD and what the research actually shows.
References
- Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344–1364. doi:10.1111/j.1476-5381.2011.01238.x
- Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Frontiers in Neurology. 2018;9:759. doi:10.3389/fneur.2018.00759. Corrigendum 2019;9:1050. doi:10.3389/fneur.2018.01050
